Table 3 Baseline demographics of the recruited haemodialysis patients
Variable | Total patients (269) | COVID-19 rRT-PCR positive (32) | COVID-19 rRT-PCR negative (237) | p-value positive vs negative |
|---|---|---|---|---|
Age, years | 61 (50–73) | 62 (54–75) | 60 (50–73) | 0.663 |
Gender, male | 177 (65.7%) | 22 (68.7%) | 150 (63.3%) | 0.546 |
Ethnicity, Caucasian | 196 (72.8%) | 25 (78%) | 171 (72.2%) | 0.476 |
BAME | 73 (27.2%) | 7 (22%) | 66 (27.8%) | Â |
Smoking history | 32 (11.9%) | 8 (25%) | 24 (10.1%) | 0.344 |
Weight, Kg | 76 (64–89.5) | 81.5 (63–95) | 75 (65–89) | 0.405 |
BMI, Kg/m2 | 27 (23–31) | 26.5 (22.5–32) | 27 (24–31) | 0.939 |
Diabetes mellitus | 97 (36.1%) | 9 (28.1%) | 88 (37.1%) | 0.319 |
CVD | 60 (22.3%) | 8 (25%) | 52 (21.9%) | 0.696 |
RASi | 93 (34.6%) | 9 (28.1%) | 84 (35.4%) | 0.414 |
Frail (CFS>/=5), n = 189 | 73/189 (38.6%) | 18/28 (64.3%) | 55/161 (34.1%) | 0.003 |
Dialysis vintage, months | 26 (11–64) | 42 (14–71) | 25 (10–61) | 0.658 |
Dialysis access, AVF | 167 (62.1%) | 21 (65.5%) | 146 (61.6%) | 0.701 |
URR, % | 72 (65–78) | 69 (66–77) | 73 (67–78) | 0.162 |
Albumin, g/L, n = 262 | 37 (34–40) | 38 (34–40) | 37 (34–40) | 0.873 |
Ferritin, ng/mL, n = 262 | 367 (208–652) | 364 (239–706) | 368 (208–647) | 0.761 |
TSats, %, n = 262 | 24 (16–34) | 27 (17–36) | 24 (16–34) | 0.418 |
Vitamin D level, nmol/L, n = 211 | 43 (28–55) | 42 (24–53) | 37 (30–71) | 0.613 |
Haemoglobin, g/L, n = 214 | 107 (96–117) | 103 (86–120) | 107 (96–117) | 0.616 |
WCC, ×109/L, n = 214 | 7 (5–8) | 6.6 (4–9) | 7 (5–8) | 0.925 |
Lymphocytes, ×109/L, n = 214 | 1.1 (0.7–1.45) | 0.75 (0.5–1.2) | 1.10 (0.8–1.5) | 0.005 |
Platelet count, ×109/L, n = 214 | 204 (157–256) | 189 (117–262) | 207 (158–254) | 0.286 |
Outcomes on follow-up | ||||
 Follow up, months | 7.6 (6.9–8.1) | 8.7 (8.1–8.9) | 7.2 (6.8–8) | < 0.001 |
 COVID-19 associated hospital admission | 28 (10.4%) | 25 (78.1%) | 3 (1.26%) | < 0.001 |
 ICU admission | 3 | 3 | 0 | – |
 Deaths | 18 (6.7%) | 6 (18.7%) | 12 (5.9%) | 0.003 |